Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update
Zero Candida Technologies (OTCQB: ZCTFF), a Femtech company developing an AI-powered medical device for women's gynecological health, reported its Q2 2025 financial results. The company reported a Q2 operating loss of $0.31 million, improved from $0.35 million in Q2 2024, while cash position strengthened to $0.46 million from $0.24 million at year-end 2024.
The company outlined key development milestones including final preclinical results by Q2 2026, laboratory validation studies in Q3 2026, pilot clinical trials in Israel by Q4 2026, and U.S. targeted clinical trials by Q3 2027. Management confirms sufficient resources to support operations for the next 12 months, with working capital of $1.53 million and total assets of $2.77 million.
Zero Candida Technologies (OTCQB: ZCTFF), società Femtech che sviluppa un dispositivo medico con IA per la salute ginecologica femminile, ha comunicato i risultati finanziari del secondo trimestre 2025. La società ha registrato una perdita operativa nel Q2 di 0,31 milioni di dollari, migliorata rispetto a 0,35 milioni nel Q2 2024, mentre la posizione di cassa è salita a 0,46 milioni rispetto a 0,24 milioni a fine 2024.
Tra i principali traguardi di sviluppo, la società prevede risultati preclinici finali entro il Q2 2026, studi di convalida di laboratorio nel Q3 2026, sperimentazioni cliniche pilota in Israele entro il Q4 2026 e trial clinici mirati negli USA entro il Q3 2027. La direzione conferma risorse sufficienti per supportare le operazioni nei prossimi 12 mesi, con un capitale circolante di 1,53 milioni e attività totali per 2,77 milioni.
Zero Candida Technologies (OTCQB: ZCTFF), una empresa Femtech que desarrolla un dispositivo médico con IA para la salud ginecológica femenina, informó sus resultados financieros del segundo trimestre de 2025. La compañía registró una pérdida operativa en el Q2 de 0,31 millones de dólares, mejorando desde 0,35 millones en el Q2 de 2024, mientras que su posición de efectivo se fortaleció hasta 0,46 millones desde 0,24 millones a finales de 2024.
Entre los hitos de desarrollo, la empresa planea resultados preclínicos finales para el Q2 de 2026, estudios de validación de laboratorio en el Q3 de 2026, ensayos clínicos piloto en Israel para el Q4 de 2026 y ensayos clínicos dirigidos en EE. UU. para el Q3 de 2027. La dirección confirma recursos suficientes para apoyar las operaciones durante los próximos 12 meses, con un capital de trabajo de 1,53 millones y activos totales por 2,77 millones.
Zero Candida Technologies (OTCQB: ZCTFF), 여성 생식기 건강을 위한 AI 기반 의료기기를 개발하는 Femtech 기업이 2025년 2분기 재무실적을 발표했습니다. 회사는 2025년 2분기 영업손실이 31만 달러로 2024년 2분기의 35만 달러에서 개선되었고, 현금 보유액은 연말 2024년의 24만 달러에서 46만 달러로 증가했습니다.
핵심 개발 이정표로는 2026년 2분기까지 최종 전임상 결과, 2026년 3분기 실험실 검증 연구, 2026년 4분기 이스라엘에서의 파일럿 임상시험, 2027년 3분기 미국 대상 임상시험을 제시했습니다. 경영진은 향후 12개월간 운영을 지원할 충분한 자원이 있음을 확인했으며, 운전자본 153만 달러와 총자산 277만 달러를 보유하고 있습니다.
Zero Candida Technologies (OTCQB: ZCTFF), une société Femtech développant un dispositif médical piloté par IA pour la santé gynécologique des femmes, a publié ses résultats financiers du deuxième trimestre 2025. La société a enregistré une perte d'exploitation au T2 de 0,31 million de dollars, améliorée par rapport à 0,35 million au T2 2024, tandis que la trésorerie s'est renforcée à 0,46 million contre 0,24 million à la clôture de 2024.
Parmi les jalons de développement, la société prévoit les résultats précliniques finaux d'ici le T2 2026, des études de validation en laboratoire au T3 2026, des essais cliniques pilotes en Israël d'ici le T4 2026 et des essais cliniques ciblés aux États-Unis d'ici le T3 2027. La direction confirme disposer de ressources suffisantes pour soutenir les opérations pendant les 12 prochains mois, avec un fonds de roulement de 1,53 million et des actifs totaux de 2,77 millions.
Zero Candida Technologies (OTCQB: ZCTFF), ein Femtech-Unternehmen, das ein KI-gestütztes Medizinprodukt für die gynäkologische Gesundheit von Frauen entwickelt, veröffentlichte seine Finanzergebnisse für Q2 2025. Das Unternehmen meldete einen Betriebsverlust im Q2 von 0,31 Mio. USD, verbessert gegenüber 0,35 Mio. USD im Q2 2024, während sich die Barmittelposition auf 0,46 Mio. USD gegenüber 0,24 Mio. USD zum Jahresende 2024 stärkte.
Zu den wichtigsten Entwicklungsmeilensteinen gehören abschließende präklinische Ergebnisse bis Q2 2026, Laborvalidierungsstudien im Q3 2026, Pilotklinische Studien in Israel bis Q4 2026 und zielgerichtete US-Studien bis Q3 2027. Das Management bestätigt ausreichende Mittel für die operative Tätigkeit der nächsten 12 Monate, mit einem Netto-Umlaufvermögen von 1,53 Mio. und Gesamtvermögen von 2,77 Mio.
- None.
- None.
"Q2 has been an important quarter for advancing our device toward human use and laying the foundation for our regulatory and clinical strategy," said Eli Ben-Haroosh, Chairman & CEO of Zero Candida Technologies. "Our discussions with leading hospitals and
Business Update
Device Progress: Advanced device validation and design refinements during the quarter.
Regulatory Pathway: Continued documentation and planning to support the Company's anticipated De Novo FDA pathway, as well as B2B and B2C strategies.
Partner Validation: Ongoing discussions with major
Macro Environment: Global regulators are tightening oversight on chemical-based health products, while health authorities continue to warn about antifungal resistance and diagnostic gaps highlighting importance for safer, non-drug alternatives.
Updated Timeline: ZCT milestones are aligned with industry growth trends:
- Q2 2026 Final preclinical results
- Q3 2026 Laboratory validation studies
- Q4 2026 Pilot clinical trial (
Israel ) - Q3 2027
U.S. targeted clinical trials
Financial Results
As previously reported, Zero Candida's primary focus is on developing the ZC–01 device and advancing pre-clinical validation, and the Company has not yet generated revenues.
Operating expenses for the three months ended June 30, 2025, were
General and administrative expenses for the three months ended June 30, 2025, were
The operating loss for Q2 FY2025 was
As of June 30, 2025, cash and cash equivalents were
For detailed financial results, please refer to Zero Candida Technologies' filings on SEDAR+.
About Zero Candida Technologies
Zero Candida Technologies, Inc. is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women's health. The Company is developing a SMART, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. This condition affects approximately
Forward-Looking Statements
This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Logo: https://mma.prnewswire.com/media/2420533/4723164/ZERO_CANDIDA_Logo.jpg
Company Contacts:
Eli Ben Haroosh
CEO & Founder
info@zero-candida.com
investors@zero-candida.com
(647) 874 3767
View original content:https://www.prnewswire.com/news-releases/zero-candida-technologies-reports-financial-results-for-three-and-six-months-ended-june-30-2025-and-provides-business-update-302544997.html
SOURCE ZERO CANDIDA LTD
